港股異動 | 禪遊科技大漲13.33% 擬斥資最多2000萬港元在公開市場回購股份
格隆匯12月4日丨禪遊科技(02660.HK)大漲13.33%,報0.68港元,成交3141萬港元,總市值7億港元。

禪遊科技昨日發佈公告,董事會擬根據書面決議案行使公司當時的股東授出的一般授權以回購公司股份,於公告日期起至下屆股東周年大會前的適當時候以合共最多2000萬港元的資金回購公開市場的股份,資金預期以公司內部資源撥付。根據回購授權,公司可以回購最多1億股股份,相當於緊隨2019年4月16日全球發售完成後已發行股份總數的10%(不包括公司於2019年5月9日刊發的公告中所載根據部分行使超額配股權已發行的股份)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.